FUSION PROTEIN PHARMACEUTICAL PREPARATIONS

Brand Owner (click to sort) Address Description
COVI-TRAPPER SORRENTO THERAPEUTICS, INC. 4955 Directors Place San Diego CA 92121 Fusion protein pharmaceutical preparations for the treatment or prevention of infectious diseases; Pharmaceutical preparations for the treatment of COVID-19/Coronavirus;
COVIDTRAP SORRENTO THERAPEUTICS, INC. 4955 Directors Place San Diego CA 92121 Fusion protein pharmaceutical preparations for the treatment or prevention of infectious diseases, namely, COVID-19 and Coronavirus; Pharmaceutical preparations for the treatment of COVID-19/Coronavirus;
 

Where the owner name is not linked, that owner no longer owns the brand

    
Technical Examples
  1. The present invention provides a human serum albumin-TIMP2 fusion protein having the amino acid sequence set forth in SEQ ID NO. 10, a polynucleotide encoding the same and a vector comprising the polynucleotide, a host cell transformed with the vector, a method for producing the human serum albumin-TIMP2 fusion protein and a pharmaceutical composition comprising the human serum albumin-TIMP2 fusion protein. The human serum albumin-TIMP2 fusion protein is stable and retains the activity of TIMP2, thus it can be used as a pharmaceutical composition to treat diseases related to angiogenesis and/or metastasis of cancer cells.